Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms VHL-targeting PROTAC analogue 7, MZ2 |
Target |
Action degraders |
Mechanism BRD4 degraders(Bromodomain-containing protein 4 degraders), VHL degraders(von Hippel-Lindau tumor suppressor degraders), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC51H64ClN9O9S2 |
InChIKeyLSELSHXLKGXPPF-BOBBFQORSA-N |
CAS Registry1797406-70-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hematologic Neoplasms | Preclinical | United States | 08 Jun 2017 | |
| Hematologic Neoplasms | Preclinical | United Kingdom | 08 Jun 2017 | |
| Solid tumor | Preclinical | United States | 08 Jun 2017 | |
| Solid tumor | Preclinical | United Kingdom | 08 Jun 2017 | |
| Neoplasms | Preclinical | United States | 16 Jun 2015 |





